Last reviewed · How we verify
0.25% Timolol Maleate Gel Forming Solution
0.25% Timolol Maleate Gel Forming Solution is a Small molecule drug developed by Kanecia Obie Zimmerman. It is currently FDA-approved.
At a glance
| Generic name | 0.25% Timolol Maleate Gel Forming Solution |
|---|---|
| Sponsor | Kanecia Obie Zimmerman |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (PHASE2)
- Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.25% Timolol Maleate Gel Forming Solution CI brief — competitive landscape report
- 0.25% Timolol Maleate Gel Forming Solution updates RSS · CI watch RSS
- Kanecia Obie Zimmerman portfolio CI
Frequently asked questions about 0.25% Timolol Maleate Gel Forming Solution
What is 0.25% Timolol Maleate Gel Forming Solution?
0.25% Timolol Maleate Gel Forming Solution is a Small molecule drug developed by Kanecia Obie Zimmerman.
Who makes 0.25% Timolol Maleate Gel Forming Solution?
0.25% Timolol Maleate Gel Forming Solution is developed and marketed by Kanecia Obie Zimmerman (see full Kanecia Obie Zimmerman pipeline at /company/kanecia-obie-zimmerman).
What development phase is 0.25% Timolol Maleate Gel Forming Solution in?
0.25% Timolol Maleate Gel Forming Solution is FDA-approved (marketed).